Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Last updated: February 23, 2016
Sponsor: Tongji Hospital
Overall Status: Trial Status Unknown

Phase

4

Condition

Leukemia

Treatment

N/A

Clinical Study ID

NCT02690922
TJXYXXW
  • Ages > 18
  • All Genders

Study Summary

The aim of our study is to improve the major molecular remission(MMR) rate and reduce the cost to treat ph(+) Acute Lymphoblastic Leukemia (ALL) by adjusting chemotherapy regimens and the dosage of Tyrosine Kinase Inhibitor (TKI). lower the classification of chemotherapy drugs, lower the side effect brought by which this would be a grateful news for the patients once this regimens gain a successful result, which is also the final aim of our efforts.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Get signed the informed consent of patients and family members

  2. Age ≥ 18 one full year of life

  3. Confirm the ph + ALL at molecular biology level

  4. Normal heart and lungs function

  5. Normal liver and kidney function

Exclusion

Exclusion Criteria:

  1. Leukemia in the nervous system

  2. Recurrent patients

  3. Allergies associated with any drug in our research

  4. At the same time with other organs' malignant tumours

  5. participating in other clinical researches at the same time

Study Design

Total Participants: 40
Study Start date:
March 01, 2016
Estimated Completion Date:
May 31, 2017

Study Description

The investigators new therapy regimens: The investigators use dexamethasone 10mg/d(d3-d7) as pre-processing therapy, dasatinib 100mg (d1-d84) plus prednisone 60mg/m2 (d1-24), reduce to d32, as inductive treatment after inductive treatment, if the patient get major molecular remission, patient will get to consolidation therapy, that is methotrexate (MTX) 3g/m2 d1, if not, this patient would be excluded from our trail. after consolidation therapy, if the patient have matched bone marrow donor, the investigators will suggest the patient receipting allogens-stem cell transplantation, otherwise, autogens stem cell transplantation can also be considered once the patient have no applicable bone marrow donor. on the other side, if the patient still not get MMR after this two cycle, maybe the patient can try Car-T, or other chemotherapy regimens.

Connect with a study center

  • Tongji hospital

    Wuhan, Hubei 430000
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.